ILD-GAP Combined with the Charlson Comorbidity Index Score (ILD-GAPC) as a Prognostic Prediction Model in Patients with Interstitial Lung Disease
Table 2
Patient’s characteristics.
Characteristics
Overall cases
IPF
CVD-IP/iNSIP
CHP
UC-ILD
value
Total number, n (%)
185 (100)
57 (30.8)
117 (63.2)
6 (3.2)
5 (2.7)
Age (years)
71.9 ± 9.1
73.3 ± 7.2
71.4 ± 9.2
67.8 ± 21.3
72.4 ± 4.0
0.608
Male sex, n (%)
124 (67.0)
49 (86.0)
66 (56.4)
4 (66.7)
5 (100)
<0.001
CCIS
2.5 ± 2.1
2.6 ± 2.0
2.5 ± 2.2
1.5 ± 1.2
2.00.7
0.611
Blood biomarker
KL-6 (U/mL)
867.7 ± 1112.2
748.3 ± 456.5
839.4 ± 1071.6
2692 ± 3265.3
405.2 ± 154.4
0.116
Pulmonary function tests
%FVC
94.2 ± 18.8
93.5 ± 18.5
94.1 ± 19.2
92.8 ± 10.8
105 ± 19.6
0.408
%FEV1
90.8 ± 19.8
87.3 ± 19.2
92.1 ± 20.4
92.7 ± 8.7
97.3 ± 19.8
0.370
%DLco
92.9 ± 29.7
81.9 ± 26.2
97.6 ± 30.2
83.1 ± 17.6
118.9 ± 25.0
0.001
Emphysematous lesion, n (%)
105 (57)
49 (86)
56 (48)
0
0
<0.001
ILD-GAP score
1.4 ± 1.4
3.0 ± 0.9
0.6 ± 0.7
0.7 ± 0.5
3.2 ± 0.4
<0.001
Treatment
Anti-fibrotic agents, n (%)
10 (5.4)
9 (15.8)
1 (0.9)
0 (0)
0 (0)
<0.001
Corticosteroid, n (%)
42 (22.7)
9 (15.8)
32 (27.4)
1 (1.6)
0 (0)
0.205
Immunosuppressant, n (%)
20 (10.8)
0 (0)
20 (17.1)
0 (0)
0 (0)
<0.001
Outcome
Follow-up (days)
792 ± 479
757 ± 469
821 ± 495
815 ± 350
484 ± 211
0.402
3-yr ILD-related events, n (%)
21 (11.4)
10 (17.5)
10 (8.5)
0 (0)
1 (0.5)
0.238
3-yr all-cause mortality, n (%)
21 (11.4)
9 (15.8)
11 (9.4)
0 (0)
1 (0.5)
0.441
Respiratory causes
15
9
5
0
1
0.040
Nonrespiratory causes
6
0
6
0
0
0.308
3-yr ILD-related events include cause specific mortality due to ILD and first AE after pulmonary function test within 3 years. Therefore, we excluded the patients who did not have experienced an AE but died of non-respiratory causes. Abbreviations: AE, acute exacerbation; CHP, chronic hypersensitivity pneumonia; CCIS, Charlson comorbidity index score; CI, confidence interval; CVD-IP, collagen vascular disease-related interstitial pneumonia; GAP, gender/age/physiology; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; KL-6, Krebs von den Lungen; %DLco, percentage predicted diffusion capacity of lung for carbon monoxide, %FVC, percentage predicted forced vital capacity; UC-ILD, unclassifiable interstitial lung disease.
